NASDAQ:COLL Collegium Pharmaceutical (COLL) Stock Price, News & Analysis $28.70 -0.13 (-0.43%) As of 12:43 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock About Collegium Pharmaceutical Stock (NASDAQ:COLL) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get COLL alerts:Sign Up Key Stats Today's Range$28.34▼$28.8150-Day Range$24.67▼$30.5652-Week Range$23.23▼$42.29Volume42,461 shsAverage Volume426,506 shsMarket Capitalization$922.03 millionP/E Ratio12.37Dividend YieldN/APrice Target$43.80Consensus RatingModerate Buy Company OverviewCollegium Pharmaceutical, Inc., a specialty pharmaceutical company, engages in the development and commercialization of medicines for pain management. Its portfolio includes Xtampza ER, an abuse-deterrent, extended-release, and oral formulation of oxycodone for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment; Nucynta ER and Nucynta IR, which are extended-release and immediate-release formulations of tapentadol, indicated for the management of acute, severe, and persistent pain; Belbuca, a buccal film that contains buprenorphine; and Symproic, an oral formulation of naldemedine for the treatment of opioid-induced constipation in adult patients with chronic non-cancer pain. The company was formerly known as Collegium Pharmaceuticals, Inc. and changed its name to Collegium Pharmaceutical, Inc. in October 2003. Collegium Pharmaceutical, Inc. was incorporated in 2002 and is headquartered in Stoughton, Massachusetts.Read More… Collegium Pharmaceutical Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks81st Percentile Overall ScoreCOLL MarketRank™: Collegium Pharmaceutical scored higher than 81% of companies evaluated by MarketBeat, and ranked 190th out of 917 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.4 / 5Analyst RatingModerate Buy Consensus RatingCollegium Pharmaceutical has received a consensus rating of Moderate Buy. The company's average rating score is 2.80, and is based on 4 buy ratings, 1 hold rating, and no sell ratings.Amount of Analyst CoverageCollegium Pharmaceutical has only been the subject of 3 research reports in the past 90 days.Read more about Collegium Pharmaceutical's stock forecast and price target. Earnings and Valuation2.5 / 5Proj. Earnings Growth7.12% Earnings GrowthEarnings for Collegium Pharmaceutical are expected to grow by 7.12% in the coming year, from $5.62 to $6.02 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Collegium Pharmaceutical is 12.34, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 24.82.Price to Earnings Ratio vs. SectorThe P/E ratio of Collegium Pharmaceutical is 12.34, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 26.69.Price to Book Value per Share RatioCollegium Pharmaceutical has a P/B Ratio of 4.78. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Short Interest0.0 / 5Short Interest LevelBearish Percentage of Shares Shorted14.75% of the float of Collegium Pharmaceutical has been sold short.Short Interest Ratio / Days to CoverCollegium Pharmaceutical has a short interest ratio ("days to cover") of 11.5, which indicates bearish sentiment.Change versus previous monthShort interest in Collegium Pharmaceutical has recently increased by 2.01%, indicating that investor sentiment is decreasing. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldCollegium Pharmaceutical does not currently pay a dividend.Dividend GrowthCollegium Pharmaceutical does not have a long track record of dividend growth. Sustainability and ESG3.0 / 5Environmental Score-2.78 Percentage of Shares Shorted14.75% of the float of Collegium Pharmaceutical has been sold short.Short Interest Ratio / Days to CoverCollegium Pharmaceutical has a short interest ratio ("days to cover") of 11.5, which indicates bearish sentiment.Change versus previous monthShort interest in Collegium Pharmaceutical has recently increased by 2.01%, indicating that investor sentiment is decreasing. News and Social Media4.1 / 5News Sentiment1.30 News SentimentCollegium Pharmaceutical has a news sentiment score of 1.30. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.69 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 12 news articles for Collegium Pharmaceutical this week, compared to 5 articles on an average week.Search Interest3 people have searched for COLL on MarketBeat in the last 30 days. This is an increase of 200% compared to the previous 30 days.MarketBeat Follows1 people have added Collegium Pharmaceutical to their MarketBeat watchlist in the last 30 days. Company Ownership0.8 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, Collegium Pharmaceutical insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $2,334,994.00 in company stock.Percentage Held by InsidersOnly 2.51% of the stock of Collegium Pharmaceutical is held by insiders.Read more about Collegium Pharmaceutical's insider trading history. Receive COLL Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Collegium Pharmaceutical and its competitors with MarketBeat's FREE daily newsletter. Email Address COLL Stock News HeadlinesBrokerages Set Collegium Pharmaceutical, Inc. (NASDAQ:COLL) Target Price at $43.80May 23 at 3:31 AM | americanbankingnews.comCollegium Pharmaceutical's (NASDAQ:COLL) Conservative Accounting Might Explain Soft EarningsMay 20 at 10:44 PM | finance.yahoo.comGold Hits New Highs as Global Markets SpiralWhen Trump took office in 2017, gold was just $1,100 an ounce. By the time he left, it had soared to $1,839. Now… as new tariffs take effect, gold is breaking records again. You've hopefully already seen this in action… but gold is surpassing $3,000 per ounce for the first time EVER.May 23, 2025 | Premier Gold Co (Ad)Collegium to Participate in Upcoming Investor ConferencesMay 19, 2025 | globenewswire.comCollegium Pharmaceutical Announces $25 Million Accelerated Share Repurchase Agreement with Jefferies LLCMay 14, 2025 | nasdaq.comCollegium Pharmaceutical enters into accelerated share repurchase agreementMay 12, 2025 | msn.comCollegium Announces $25 Million Accelerated Share Repurchase ProgramMay 12, 2025 | globenewswire.comTruist Financial Sticks to Their Buy Rating for Collegium Pharmaceutical (COLL)May 11, 2025 | theglobeandmail.comSee More Headlines COLL Stock Analysis - Frequently Asked Questions How have COLL shares performed this year? Collegium Pharmaceutical's stock was trading at $28.65 at the start of the year. Since then, COLL stock has decreased by 0.0% and is now trading at $28.64. View the best growth stocks for 2025 here. How were Collegium Pharmaceutical's earnings last quarter? Collegium Pharmaceutical, Inc. (NASDAQ:COLL) posted its earnings results on Thursday, May, 8th. The specialty pharmaceutical company reported $1.49 earnings per share (EPS) for the quarter, missing the consensus estimate of $1.50 by $0.01. The firm's revenue was up 22.7% on a year-over-year basis. Read the conference call transcript. When did Collegium Pharmaceutical IPO? Collegium Pharmaceutical (COLL) raised $75 million in an initial public offering (IPO) on Thursday, May 7th 2015. The company issued 5,800,000 shares at a price of $12.00-$14.00 per share. Jefferies and Piper Jaffray acted as the underwriters for the IPO and Wells Fargo Securities and Needham & Company were co-managers. Who are Collegium Pharmaceutical's major shareholders? Top institutional investors of Collegium Pharmaceutical include Eventide Asset Management LLC (8.21%), Vanguard Group Inc. (6.99%), Invesco Ltd. (5.08%) and Principal Financial Group Inc. (4.90%). Insiders that own company stock include Joseph Ciaffoni, Colleen Tupper, Scott Dreyer, Shirley R Kuhlmann, Thomas B Smith, Garen G Bohlin and Michael Thomas Heffernan. View institutional ownership trends. How do I buy shares of Collegium Pharmaceutical? Shares of COLL stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Collegium Pharmaceutical own? Based on aggregate information from My MarketBeat watchlists, some other companies that Collegium Pharmaceutical investors own include NVIDIA (NVDA), Meta Platforms (META), Advanced Micro Devices (AMD), Broadcom (AVGO), Arista Networks (ANET), Netflix (NFLX) and CrowdStrike (CRWD). Company Calendar Last Earnings5/08/2025Today5/23/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:COLL CIK1267565 Webwww.collegiumpharma.com Phone(781) 713-3699FaxN/AEmployees210Year FoundedN/APrice Target and Rating Average Stock Price Target$43.80 High Stock Price Target$50.00 Low Stock Price Target$37.00 Potential Upside/Downside+52.0%Consensus RatingModerate Buy Rating Score (0-4)2.80 Research Coverage5 Analysts Profitability EPS (Most Recent Fiscal Year)$1.22 Trailing P/E Ratio12.42 Forward P/E Ratio5.13 P/E GrowthN/ANet Income$48.15 million Net Margins14.78% Pretax Margin21.36% Return on Equity104.67% Return on Assets18.38% Debt Debt-to-Equity Ratio3.43 Current Ratio0.97 Quick Ratio0.88 Sales & Book Value Annual Sales$664.28 million Price / Sales1.39 Cash Flow$10.44 per share Price / Cash Flow2.76 Book Value$5.99 per share Price / Book4.81Miscellaneous Outstanding Shares32,132,000Free Float30,966,000Market Cap$926.04 million OptionableOptionable Beta0.63 Social Links These 7 Stocks Will Be Magnificent in 2025Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2025. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.Get This Free Report This page (NASDAQ:COLL) was last updated on 5/23/2025 by MarketBeat.com Staff From Our PartnersMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | SponsoredTrump’s treachery Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredBuffett’s favorite chart just hit 209% – here’s what that means for goldA Historic Gold Announcement Is About to Rock Wall Street For months, sharp-eyed analysts have watched the ...Golden Portfolio | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredTrump’s Bitcoin Reserve is No Accident…Bitcoin's supply is being drained at unprecedented rates, but while most investors focus solely on Bitcoin, th...Crypto 101 Media | SponsoredIs President Trump Lying To You With This?President Trump’s economic transition isn’t without hardship. But what if there were a smart, tax-free way to ...Colonial Metals | SponsoredJuly 2025 Rule Change to Impact Retirement InvestorsThere's a massive change from a new rule going into effect this July. And it's one the Big Banks are alread...Premier Gold Co | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Collegium Pharmaceutical, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Collegium Pharmaceutical With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.